Type 2 Diabetes

A cross-sectional study of more than 1000 patients suggests presence of MACS in patients with benign adrenal tumors was associated with increased prevalence and severity of hypertension as well as an increase in the likelihood of requiring insulin therapy in type 2 diabetes.

The estimated prevalence of diabetes increased from 10.9% in 2013 to 12.4% in 2018, without a significant improvement seen in adequate treatment.

An analysis of data from more than 1.1 million patients provides an overview of inequities in use of GLP-1 RAs among patients with diabetes based on racial/ethnic background and household income.

The American Academy of Neurology released guidelines detailing oral and topical treatment options for management of painful diabetic neuropathy on December 27.

Data show Asian, Black, and Hispanic patients and those with lower income were less likely to receive treatment with GLP-1 RAs.

The latest endocrine case report from Brady Pregerson, MD, features a man in his 60s with diabetes and left below-knee amputation for a smelly right foot that has been getting gradually worse for 2 weeks. Check out the report, labs, and imaging and see if you can determine the correct diagnosis.

Dr. Shapiro discusses the implantable VC-02 device success in producing C-peptide in patients with type 1 diabetes and what is coming next.

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. December's month in review features new guidelines, FDA news, and more.

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. December's month in review features new guidelines, stories on the effect of delayed visits, and more.

A high-potential drug for type 1 diabetes may not have received regulation this year, but it sparked vital conversation among experts.

A trial comparing changes in blood glucose before, during, and after exercise at sea level and simulated altitude provides insight into the potential increase in risk for hypoglycemia among patients with type 1 diabetes.

Dr. Jellinger discusses the lipid section of the DCRM guidelines, the role of combination therapies in lowering LDL and what is coming next for the field of diabetes in 2022.

The American Diabetes Association has released their 2022 Standards of Medical Care in Diabetes, which includes updates or additional guidance in areas such as diabetes screenings, first-line therapies, and technology use.

Limitations managing type 2 diabetes with new technologies used as monitoring tools that need to be addressed moving forward.

Guidance in terms of counseling women on pregnancy, gestational diabetes, and the risk for cardiovascular events.

A description of hybrid artificial insulin pump systems for type 2 diabetes and a discussion highlighting potential integration with continuous glucose monitoring systems.

Recommendations to address accessibility and coverage issues that affect the use of continuous glucose monitoring into widespread clinical practice.

A discussion on using continuous glucose monitoring systems to improve the management of type 2 diabetes.

The benefits of using new therapies, such as SGLT2 inhibitors and GLP-1 receptor agonists, to treat type 2 diabetes.

Guidance on the use of aspirin therapy in patients at risk of cardiovascular events, based on recently updated guideline recommendations.

Considerations that factor into decisions for reducing LDL levels in patients with diabetes with statin therapy or options, such as PCSK9 inhibitors and ezetimibe.

A call to action for more focus on the management of the type 2 diabetes epidemic around the globe.

A study presented at RSNA 2021 suggests sonographic quantitative assessment of the deltoid muscle could provide a simple and noninvasive screening method for detection of type 2 diabetes.

An analysis of Medicare fee-for-service data from 2017-2019 details the widening gaps in access to newer diabetes technologies for non-White patients in the US.